BRAF and melanoma: In addition, reduction of Mitf activity sensitizes melanoma, a highly chemotherapy-resistant neoplasm, to chemotherapeutic agents, and it has been suggested that targeting Mitf in combination with B-RAF or cyclin dependent kinases inhibitors may offer a rational therapeutic avenue into melanoma [62].